STOCK TITAN

Clorox (NYSE: CLX) director receives new deferred stock units awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Clorox director Stephanie Plaines reported routine compensation-related awards of deferred stock units, not open-market trades. She acquired 288.1391 deferred stock units on June 30, 2026 and 103.9395 units on May 8, 2026, both at a stated price of $0.

The units were granted under the Independent Directors' Deferred Compensation Plan, including amounts acquired through dividend reinvestment and in lieu of quarterly director fees. After these awards, she held a total of 8,117.1272 deferred stock units, which will be settled entirely in Clorox common stock when she retires from, or otherwise leaves, the board.

Positive

  • None.

Negative

  • None.
Insider Plaines Stephanie
Role null
Type Security Shares Price Value
Grant/Award Deferred Stock Units 288.139 $0.00 --
Grant/Award Deferred Stock Units 103.94 $0.00 --
Holdings After Transaction: Deferred Stock Units — 8,117.127 shares (Direct, null)
Footnotes (1)
  1. 1-for-1 Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.
Deferred stock units granted 288.1391 units Award on June 30, 2026
Deferred stock units granted 103.9395 units Award on May 8, 2026
Total deferred stock units held 8,117.1272 units Holdings after June 30, 2026 award
Price per deferred unit $0.0000 per unit Both reported awards
Underlying common stock 1-for-1 ratio Each deferred unit to one CLX share at settlement
Deferred Stock Units financial
"Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan."
Deferred stock units are promises from a company to give an employee shares of stock at a future date, often after certain conditions are met or after leaving the company. They function like a form of delayed compensation, allowing employees to earn shares over time. For investors, they represent potential future ownership in the company, but do not provide immediate voting rights or dividends until the shares are actually received.
Independent Directors' Deferred Compensation Plan financial
"Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan."
A deferred compensation plan for independent directors lets outside board members postpone receiving part of their fees or stock awards until a later date, often when they retire or leave the board. Think of it as choosing to put pay into a company-run savings plan that grows and pays out later; it matters to investors because it affects director incentives, future cash or share obligations, and how aligned independent directors are with long-term company performance.
dividend reinvestment financial
"Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan."
Dividend reinvestment is when the money earned from a company's profit sharing, called dividends, is automatically used to buy more shares of that company instead of being received as cash. This process helps investors grow their holdings over time without extra effort, much like using earned interest to buy more of a savings account. It encourages long-term investment growth by continuously increasing the amount of shares owned.
quarterly director's fees financial
"Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Plaines Stephanie

(Last)(First)(Middle)
1221 BROADWAY

(Street)
OAKLAND CALIFORNIA 94612-1888

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
CLOROX CO /DE/ [ CLX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Deferred Stock Units(1)05/08/2026A(2)V103.9395 (3) (3)Common Stock103.9395$0.00007,828.9881D
Deferred Stock Units(1)06/30/2026A(4)288.1391 (3) (3)Common Stock288.1391$0.00008,117.1272D
Explanation of Responses:
1. 1-for-1
2. Deferred Stock Units acquired through dividend reinvestment during the fiscal year pursuant to the Independent Directors' Deferred Compensation Plan.
3. The Deferred Stock Units will be settled 100% in Clorox stock in connection with the reporting person's retirement or other termination of service as a Director.
4. Receipt of Deferred Stock Units in lieu of receipt of quarterly director's fees.
By Jinho Joo, Attorney-in-Fact07/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Clorox (CLX) director Stephanie Plaines report in this Form 4?

Stephanie Plaines reported receiving additional deferred stock units as part of her director compensation at Clorox. The awards reflect routine grants, including dividend reinvestment and fee deferrals, with no open-market buying or selling of Clorox common stock disclosed in this filing.

How many deferred stock units did Stephanie Plaines receive from Clorox (CLX)?

She received 288.1391 deferred stock units on June 30, 2026 and 103.9395 units on May 8, 2026. These awards increased her total deferred stock unit holdings to 8,117.1272 units, all linked on a one-for-one basis to Clorox common stock.

Are the Clorox (CLX) deferred stock units a market purchase or sale?

The deferred stock units are compensation-related awards, not market purchases or sales. They were received through dividend reinvestment and in lieu of quarterly director fees under Clorox’s Independent Directors' Deferred Compensation Plan, at a stated price of $0 per unit.

When will Stephanie Plaines’s Clorox (CLX) deferred stock units be settled?

The deferred stock units will be settled entirely in Clorox common stock upon her retirement or other termination of service as a director. Until then, they remain deferred awards linked to the company’s stock rather than immediately deliverable shares.

What does the one-for-one feature of Clorox (CLX) deferred stock units mean?

The one-for-one feature means each deferred stock unit corresponds to one share of Clorox common stock upon settlement. This structure ties the value of the director’s deferred compensation directly to Clorox’s share performance over time, aligning board compensation with shareholder outcomes.

Did the Clorox (CLX) Form 4 show any insider sales or option exercises?

The Form 4 did not show any insider sales or option exercises. It only reported two acquisitions of deferred stock units as compensation awards, classified under code “A” for grant or other acquisition, with no open-market buy or sell transactions indicated.